Authorized purpose: Measures maximal right- and left-ventricular diameters from volumetric CTPA and reports their ratio.
Clinical role
AI measures maximal right and left ventricular diameters on CTPA and reports their ratio with annotated images; DICOM results go to PACS for physician review to assist assessment of right ventricle enlargement, not for stand-alone clinical decision-making.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: Not for stand-alone clinical decision-making and must not preclude clinical assessment; other FDA limitations are unknown.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Measures maximal right- and left-ventricular diameters from volumetric CTPA and reports their ratio.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Contrast-enhanced chest CT using a standard CTPA acquisition.
Who uses it?Intended users: Thoracic radiologists, general radiologists, pulmonologists, cardiologists, or similar physicians.
What does the software produce?Output: DICOM annotated image series and RV/LV summary report showing ventricular measurements, maximal diameters, and the RV/LV ratio.
What is its most important limitation?Key limitation: Not for stand-alone clinical decision-making and must not preclude clinical assessment; other FDA limitations are unknown.
Clinical takeaway. Clinical role: Measures maximal right- and left-ventricular diameters from volumetric CTPA and reports their ratio.
Evidence takeaway. Evidence from the reviewed source record: FDA reports clinical comparison against trained-radiologist ground truth, mean absolute error below 7.2 mm, and 4 clinical sites; sample size and sensitivity/specificity are not reported.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Measures maximal right- and left-ventricular diameters from volumetric CTPA and reports their ratio.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
AI measures maximal right and left ventricular diameters on CTPA and reports their ratio with annotated images; DICOM results go to PACS for physician review to assist assessment of right ventricle enlargement, not for stand-alone clinical decision-making.
Exact FDA submission
Checked 2026-11-14
Packet wording: "uses a locked artificial intelligence machine learning (AI/ML) algorithm to measure the maximal diameters of the right and left ventricles of the heart from a computed tomography pulmonary angiogram (CTPA) and report the ratio of those measurements." … "The results of the analysis are exported in DICOM format are sent to a PACS destination for review by thoracic radiologists, general radiologists, pulmonologists, cardiologists, or other similar physicians to assist in the assessment of right ventricle enlargement.". Read from the exact FDA decision document on 2026-11-14.
FDA reports clinical comparison against trained-radiologist ground truth, mean absolute error below 7.2 mm, and 4 clinical sites; sample size and sensitivity/specificity are not reported.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA reports clinical comparison against trained-radiologist ground truth, mean absolute error below 7.2 mm, and 4 clinical sites; sample size and sensitivity/specificity are not reported.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Viz RV/LV regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K221100
Sites4
IndependenceIndependence not established
K221100
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K221100. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Contrast-enhanced chest CT using a standard CTPA acquisition.
Scope: Exact FDA submission. FDA input scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Viz RV/LV as hosted on Viz.ai’s Backend Server, which analyzes applicable CTPA scans acquired on CT scanners and forwarded to that server. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Viz RV/LV is hosted on Viz.ai’s Backend Server and analyzes applicable CTPA scans that are acquired on CT scanners and are forwarded to Viz.ai’s Backend Server.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: DICOM annotated image series and RV/LV summary report showing ventricular measurements, maximal diameters, and the RV/LV ratio.
Scope: Exact FDA submission. FDA output description.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: DICOM annotated image series and RV/LV summary report showing ventricular measurements, maximal diameters, and the RV/LV ratio.
Scope: Exact FDA submission. FDA output description.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Viz RV/LV as hosted on Viz.ai’s Backend Server, which analyzes applicable CTPA scans acquired on CT scanners and forwarded to that server. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Viz RV/LV is hosted on Viz.ai’s Backend Server and analyzes applicable CTPA scans that are acquired on CT scanners and are forwarded to Viz.ai’s Backend Server.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Viz.ai's own news releases say the Viz.ai One platform completed a SOC 2 Type II + HIPAA audit (announced 2024-02-26) and received ISO 27001:2022 plus six other ISO certificates (announced 2024-07-10). These are vendor announcements; the report and certificates were not read, and certificate dates may have lapsed or renewed since.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Viz.ai's trust center states that its assurance program includes continuously monitored controls, SOC 2 Type II coverage that includes the availability criterion for Viz.ai production systems and supporting infrastructure, ISO 22301 business continuity certification to ensure uninterrupted clinical workflows, and ISO 27035 incident management certification.
Vendor-wide
Checked 2026-10-27
Vendor statements, not attestations. Certificates and audit reports were not read; the trust center names Viz.ai generally and does not scope these commitments to any specific product release; exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Care setting: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state a care setting or patient population for the subject device. Confirm intended sites and patients with the vendor and local policy.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K221100 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.